Drug Search Results
More Filters [+]

MB-097

Alternative Names: MB-097, MB097, MB 097
Latest Update: 2024-08-27
Latest Update Note: News Article

Product Description

MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy. MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same patient cohort in which it will be tested. (Sourced from: https://microbiotica.com/microbioticas-live-bacterial-therapeutic-mb097-in-development-to-begin-clinical-trials-in-2022-in-immuno-oncology/)

Mechanisms of Action: Microbiome Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Microbiotica
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MB-097

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MELODY-1

P1

Not yet recruiting

Melanoma

2025-12-01

Recent News Events